Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?
NCT ID NCT07720258
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer will receive the drug intravenously every two weeks. The study aims to see how many patients respond and how long the benefit lasts, while also exploring why some tumors respond and others do not.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called sacituzumab tirumotecan that targets the TROP2 protein on cancer cells
- What this could lead to
- If effective, this could become a new second-line treatment option for a rare cancer with no standard therapy after platinum-based chemotherapy fails.
- What could go wrong
- This is a small, single-arm phase II trial with only 27 participants, so results may not generalize. The drug also carries risks of toxicity, including infusion reactions and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SMALL BOWEL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
Nagoya, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hiroshima University Hospital
Hiroshima, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kyushu University Hospital
Fukuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital
Tokyo, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.